Regulation and gene expression of heme synthesis under heavy metal exposure-review

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 29, Issue 2, 2010, Pages 137-158

  Schauder, Avital ^a   Avital, Almog ^a   Malik, Zvi ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

ALAD; Ga; Heavy metals; Heme; Iron; Pb; PBGD

Indexed keywords

ALUMINUM; AMINOLEVULINIC ACID; CADMIUM; COPPER; FERROCHELATASE; GALLIUM; HEAVY METAL; HEME; HYDROLYASE; IRON; LEAD; MERCURY; PORPHOBILINOGEN DEAMINASE; PROTOPORPHYRIN; 5 AMINOLEVULINATE SYNTHASE; HEME OXYGENASE; PORPHOBILINOGEN SYNTHASE;

AMINO ACID SEQUENCE; ANEMIA; AWARENESS; BIOINFORMATICS; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; ENZYME DEGRADATION; GENE EXPRESSION; HEART DISEASE; HEAVY METAL POISONING; HEME SYNTHESIS; HOMEOSTASIS; HUMAN; IRON TRANSPORT; KIDNEY FAILURE; MENTAL DISEASE; NEOPLASM; OXIDATIVE STRESS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN BINDING; REGULATORY MECHANISM; REVIEW; RISK FACTOR; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LEAD POISONING; METABOLISM; PHOTOCHEMOTHERAPY; TOXICITY;

5-AMINOLEVULINATE SYNTHETASE; ANIMALS; CADMIUM; COPPER; FERROCHELATASE; GENE EXPRESSION REGULATION; HEME; HEME OXYGENASE (DECYCLIZING); HOMEOSTASIS; HUMANS; HYDROXYMETHYLBILANE SYNTHASE; IRON; LEAD POISONING; METALS, HEAVY; PHOTOCHEMOTHERAPY; PORPHOBILINOGEN SYNTHASE;

EID: 77953348988     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvironPatholToxicolOncol.v29.i2.70     Document Type: Review

References (127)

1. Ponka P. Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. Blood. 1997;89(1):1-25.
2. Hamilton JW, Bement WJ, Sinclair PR, Sinclair JF, Alcedo JA, Wetterhahn KE. Heme regulates hepatic 5-aminolevulinate synthase mRNA expression by decreasing mRNA half-life and not by altering its rate of transcription. Arch Biochem Biophys. 1991;289(2):387-92.
3. Igarashi K, Sun J. The heme-Bach1 pathway in the regulation of oxidative stress response and erythroid differentiation. Antioxid Redox Signal. 2006;8(1-2)107-18.
4. Feuerstein T, Schauder A, Malik Z. Silencing of ALA dehydratase affects ALA-photodynamic therapy effi cacy in K562 erythroleukemic cells. Photochem Photobiol Sci. 2009;8(10)1461-6.
5. Cox TC, Bawden MJ, Martin A, May BK. Human erythroid 5-aminolevulinate synthase: promoter analysis and identifi cation of an iron-responsive element in the mRNA. EMBO J 1991;10(7):1891-902.
6. Rouault TA. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol. 2006;2(8):406-14.
7. Oh-hama T. Evolutionary consideration on 5-aminolevulinate synthase in nature. Orig Life Evol Biosph. 1997;27(4):405-12
8. Ajioka RS, Phillips JD, Kushner JP. Biosynthesis of heme in mammals. Biochim Biophys Acta. 2006;1763(7):723-36.
9. Bishop DF, Henderson AS, Astrin KH. Human deltaaminolevulinate synthase: assignment of the housekeeping gene to 3p21 and the erythroid-specific gene to the X chromosome. Genomics. 1990;7(2):207-14.
10. Conboy JG, Cox TC, Bottomley SS, Bawden MJ, May BK. Human erythroid 5-aminolevulinate synthase. Gene structure and species-specific differences in alternative RNA splicing. J Biol Chem. 1992;267(26):18753-8.
11. Lathrop JT, Timko MP. Regulation by heme of mitochondrial protein transport through a conserved amino acid motif. Science. 1993;259(5094):522-5.
12. Munakata H, Sun JY, Yoshida K, Nakatani T, Honda E, Hayakawa S, Furuyama K, Hayashi N. Role of the heme regulatory motif in the heme-mediated inhibition of mitochondrial import of 5-aminolevulinate synthase. J Biochem. 2004;136(2):233-8.
13. McLintock LA, Fitzsimons EJ. Erythroblast iron metabolism in sideroblastic and sideropenic states. Hematology. 2002;7(3):189-95.
14. Muckenthaler MU, Galy B, Hentze MW. Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr. 2008;28:197-213.
15. Wingert RA, Galloway JL, Barut B, Foott H, Fraenkel P, Axe JL, Weber GJ, Dooley K, Davidson AJ, Schmid B, Paw BH, Shaw GC, Kingsley P, Palis J, Schubert H, Chen O, Kaplan J, Zon LI. Defi ciency of glutaredoxin 5 reveals Fe-S clusters are required for vertebrate haem synthesis. Nature. 2005;436(7053): 1035-9.
16. Camaschella C. Recent advances in the understanding of inherited sideroblastic anaemia. Br J Haematol. 2008;143(1):27-38.
17. Fukuda Y, Fujita H, Garbaczewski L, Sassa S. Regulation of beta-globin mRNA accumulation by heme in dimethyl sulfoxide (DMSO)-sensitive and DMSOresistant murine erythroleukemia cells. Blood. 1994;83(6):1662-7.
18. Meguro K, Igarashi K, Yamamoto M, Fujita H, Sassa S. The role of the erythroid-specific delta-aminolevulinate synthase gene expression in erythroid heme synthesis. Blood. 1995;86(3):940-8.
19. Scholnick PL, Hammaker LE, Marver HS. Solubleaminolevulinic acid synthetase of rat liver. II. Studies related to the mechanism of enzyme action and hemin inhibition. J Biol Chem. 1972;247(13):4132-7.
20. Sassa S. Delta-aminolevulinic acid dehydratase assay. Enzyme. 1982;28(2-3):133-45.
21. Kaya AH, Plewinska M, Wong DM, Desnick RJ, Wetmur JG. Human delta-aminolevulinate dehydratase (ALAD) gene: structure and alternative splicing of the erythroid and housekeeping mRNAs. Genomics. 1994;19(2):242-8.
22. Jaffe EK, Martins J, Li J, Kervinen J, Dunbrack RL, Jr. The molecular mechanism of lead inhibition of human porphobilinogen synthase. J Biol Chem. 2001;276(2):1531-7.
23. Muller WE, Snyder SH. delta-Aminolevulinic acid: infl uences on synaptic GABA receptor binding may explain CNS symptoms of porphyria. Ann Neurol. 1977;2(4):340-2.
24. Jaffe EK, Stith L. ALAD porphyria is a conformational disease. Am J Hum Genet. 2007;80(2):329-37.
25. Guo GG, Gu M, Etlinger JD. 240-kDa proteasome inhibitor (CF-2) is identical to delta-aminolevulinic acid dehydratase. J Biol Chem. 1994;269(17): 12399-402.
26. Gross M, Hessefort S, Olin A. Purifi cation of a 38-kDa protein from rabbit reticulocyte lysate which promotes protein renaturation by heat shock protein 70 and its identifi cation as delta-aminolevulinic acid dehydratase and as a putative DnaJ protein. J Biol Chem. 1999;274(5):3125-34.
27. Pearson WR. Searching protein sequence libraries: comparison of the sensitivity and selectivity of the Smith-Waterman and FASTA algorithms. Genomics. 1991;11(3):635-50.
28. Smith TF, Waterman MS, Fitch WM. Comparative biosequence metrics. J Mol Evol. 1981;18(1):38-46.
29. Greenbaum L, Gozlan Y, Schwartz D, Katcoff DJ, Malik Z. Nuclear distribution of porphobilinogen deaminase (PBGD) in glioma cells: a regulatory role in cancer transformation? Br J Cancer. 2002;86(6):1006-11.
30. Ickowicz SD, Gozlan Y, Greenbaum L, Babushkina T, Katcoff DJ, Malik Z. Differentiation-dependent photodynamic therapy regulated by porphobilinogen deaminase in B16 melanoma. Br J Cancer. 2004;90(9):1833-41.
31. Deybach JC, Puy H. Porphobilinogen deaminase gene structure and molecular defects. J Bioenerg Biomembr. 1995;27(2):197-205.
32. Chretien S, Dubart A, Beaupain D, Raich N, Grandchamp B, Rosa J, Goossens M, Romeo PH. Alternative transcription and splicing of the human porphobilinogen deaminase gene result either in tissue-specific or in housekeeping expression. Proc Natl Acad Sci USA. 1988;85(1):6-10.
33. Porcher C, Pitiot G, Plumb M, Lowe S, de Verneuil H, Grandchamp B. Characterization of hypersensitive sites, protein-binding motifs, and regulatory elements in both promoters of the mouse porphobilinogen deaminase gene. J Biol Chem. 1991;266(16):10562-9.
34. Grunberg-Etkovitz N, Greenbaum L, Grinblat B, Malik Z. Proteasomal degradation regulates expression of porphobilinogen deaminase (PBGD) mutants of acute intermittent porphyria. Biochim Biophys Acta. 2006;1762(9):819-27.
35. Hrdinka M, Puy H, Martasek P. May 2006 update in porphobilinogen deaminase gene polymorphisms and mutations causing acute intermittent porphyria: comparison with the situation in Slavic population. Physiol Res. 2006;55 Suppl 2:S119-36.
36. Helson L, Braverman S, Mangiardi J. delta-Aminolevulinic acid effects on neuronal and glial tumor cell lines. Neurochem Res. 1993;18(12):1255-8.
37. Taketani S, Inazawa J, Nakahashi Y, Abe T, Tokunaga R. Structure of the human ferrochelatase gene. Exon/intron gene organization and location of the gene to chromosome 18. Eur J Biochem. 1992;205(1):217-222.
38. Burden AE, Wu C, Dailey TA, Busch JL, Dhawan IK, Rose JP , Wang B, Dailey HA. Human ferrochelatase: crystallization, characterization of the [2Fe-2S] cluster and determination that the enzyme is a homodimer. Biochim Biophys Acta. 1999;1435(1-2):191-7.
39. Karr SR, Dailey HA. The synthesis of murine ferrochelatase in vitro and in vivo. Biochem J. 1988;254(3):799-803.
40. Crouse BR, Sellers VM, Finnegan MG, Dailey HA, Johnson MK. Site-directed mutagenesis and spectroscopic characterization of human ferrochelatase: identification of residues coordinating the [2Fe-2S] cluster. Biochemistry. 1996;35(50):16222-9.
41. Crooks DR, Ghosh MC, Haller RG, Tong WH, Rouault TA. Posttranslational stability of the heme biosynthetic enzyme ferrochelatase is dependent on iron availability and intact iron-sulfur cluster assembly machinery. Blood. 2010;115(4):860-9.
42. Todd DJ. Erythropoietic protoporphyria. Br J Dermatol. 1994;131(6):751-66.
43. Lecha M, Puy H, Deybach JC. Erythropoietic protoporphyria. Orphanet J Rare Dis. 2009;4:19.
44. Ferreira GC. Ferrochelatase binds the iron-responsive element present in the erythroid 5-aminolevulinate synthase mRNA. Biochem Biophys Res Commun. 1995;214(3):875-8.
45. Taketani S, Adachi Y, Nakahashi Y. Regulation of the expression of human ferrochelatase by intracellular iron levels. Eur J Biochem. 2000;267(15):4685- 92.
46. Chang CS, Sassa S. Effects of metalloporphyrins on hemoglobin formation in mouse Friend virus-transformed erythroleukemia cells. Stimulation of heme biosynthesis by cobalt protoporphyrin. J Biol Chem. 1982;257(7):3650-4.
47. Labbe RF, Vreman HJ, Stevenson DK. Zinc protoporphyrin: A metabolite with a mission. Clin Chem. 1999;45(12):2060-72.
48. Medlock AE, Carter M, Dailey TA, Dailey HA, Lanzilotta WN. Product release rather than chelation determines metal specificity for ferrochelatase. J Mol Biol. 2009;393(2):308-19.
49. Pae HO, Chung HT. Heme oxygenase-1: its therapeutic roles in infl ammatory diseases. Immune Netw. 2009;9(1):12-9.
50. Wagener FA, Volk HD, Willis D, Abraham NG, Soares MP, Adema GJ, Figdor CG. Different faces of the heme-heme oxygenase system in inflammation. Pharmacol Rev. 2003;55(3):551-71.
51. Park EJ, Lim JH, Nam SI, Park JW, Kwon TK. Rottlerin induces heme oxygenase-1 (HO-1) up-regulation through reactive oxygen species (ROS) dependent and PKC delta-independent pathway in human colon cancer HT29 cells. Biochimie. 2010;92(1):110-5.
52. Sassa S. [Gene regulation by free heme]. Nippon Yakurigaku Zasshi. 2007;130(4):248-51.
53. Atamna H, Frey WH. A role for heme in Alzheimers disease: heme binds amyloid beta and has altered metabolism. Proc Natl Acad Sci USA. 2004;101(30):11153-8.
54. Pae HO, Lee YC, Chung HT. Heme oxygenase-1 and carbon monoxide: emerging therapeutic targets in inflammation and allergy. Recent Pat Infl amm Allergy Drug Discov. 2008;2(3):159-65.
55. Ryter SW, Otterbein LE, Morse D, Choi AM. Heme oxygenase/carbon monoxide signaling pathways: regulation and functional signifi cance. Mol Cell Biochem. 2002;234-5(1-2):249-63.
56. Alam J, Cook JL. How many transcription factors does it take to turn on the heme oxygenase-1 gene? Am J Respir Cell Mol Biol. 2007;36(2):166-74.
57. Andreadi CK, Howells LM, Atherfold PA, Manson MM. Involvement of Nrf2, p38, B-Raf, and nuclear factor-kappaB, but not phosphatidylinositol 3-kinase, in induction of hemeoxygenase-1 by dietary polyphenols. Mol Pharmacol. 2006;69(3):1033-40.
58. Zenke-Kawasaki Y, Dohi Y, Katoh Y, Ikura T, Ikura M, Asahara T, Tokunaga F, Iwai K, Igarashi K. Heme induces ubiquitination and degradation of the transcription factor Bach1. Mol Cell Biol. 2007;27(19):6962-71.
59. Motohashi H, Yamamoto M. Nrf2-Keap1 defi nes a physiologically important stress response mechanism. Trends Mol Med. 2004;10(11):54-57.
60. Sun J, Brand M, Zenke Y, Tashiro S, Groudine M, Igarashi K. Heme regulates the dynamic exchange of Bach1 and NF-E2-related factors in the Maf transcription factor network. Proc Natl Acad Sci USA. 2004;101(6):1461-6.
61. Richardson DR, Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta. 1997;1331(1):1-40. (Pubitemid 27168147)
62. Chua AC, Klopcic B, Lawrance IC, Olynyk JK, Trinder D. Iron: an emerging factor in colorectal carcinogenesis. World J Gastroenterol. 2010; 16(6):663-72.
63. Olynyk JK, Trinder D, Ramm GA, Britton RS, Bacon BR. Hereditary hemochromatosis in the post-HFE era. Hepatology. 2008;48(3):991-1001.
64. Brewer GJ. Iron and copper toxicity in diseases of aging, particularly atherosclerosis and Alzheimers disease. Exp Biol Med (Maywood). 2007;232(2): 323-35.
65. Zhang AS, Enns CA. Molecular mechanisms of normal iron homeostasis. Hematology Am Soc Hematol Educ Program. 2009;207-14.
66. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin regulates cellular iron effl ux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090-3.
67. Rivera S, Liu L, Nemeth E, Gabayan V, Sorensen OE, Ganz T. Hepcidin excess induces the sequestra-tion of iron and exacerbates tumor-associated anemia. Blood. 2005;105(4):1797-802.
68. Hershberger CL, Larson JL, Arnold B, Rosteck PR, Jr., Williams P, DeHoff B Dunn P, ONeal KL, Riemen MW, Tice PA. A cloned gene for human transferrin. Ann N Y Acad Sci. 1991;646:140-54.
69. Dautry-Varsat A, Ciechanover A, Lodish HF. pH and the recycling of transferrin during receptormediated endocytosis. Proc Natl Acad Sci USA. 1983;80(8):2258-62.
70. Samaniego F, Chin J, Iwai K, Rouault TA, Klausner RD. Molecular characterization of a second iron-responsive element binding protein, iron regulatory protein 2. Structure, function, and post-translational regulation. J Biol Chem. 1994;269(49):30904-10.
71. Vashisht AA, Zumbrennen KB, Huang X, Powers DN, Durazo A, Sun D, Bhaskaran N, Persson A, Uhlen M, Sangfelt O, Spruck C, Leibold EA, Wohlschlegel JA. Control of iron homeostasis by an iron-regulated ubiquitin ligase. Science. 2009;326(5953):718-21.
72. Kato J, Kobune M, Ohkubo S, Fujikawa K, Tanaka M, Takimoto R, Takada K, Takahari D, Kawano Y, Kohgo Y, Niitsu Y. Iron/IRP-1-dependent regulation of mRNA expression for transferrin receptor, DMT1 and ferritin during human erythroid differentiation. Exp Hematol. 2007;35(6):879-87.
73. Cavill I. Erythropoiesis and iron. Best Pract Res Clin Haematol. 2002;15(2):399-409.
74. Furuyama K, Kaneko K, Vargas PD. Heme as a magnifi cent molecule with multiple missions: heme determines its own fate and governs cellular homeostasis. Tohoku J Exp Med. 2007;213(1):1-16.
75. Chen JJ. Regulation of protein synthesis by the heme-regulated eIF2alpha kinase: relevance to anemias. Blood. 2007;109(7):2693-9.
76. Sheftel A, Stehling O, Lill R. Iron-sulfur proteins in health and disease. Trends Endocrinol Metab. 2010; 21(5):302-14.
77. Nilsson R, Schultz IJ, Pierce EL, Soltis KA, Naranuntarat A, Ward DM, Baughman JM, Paradkar PN, Kingsley PD, Culotta VC, Kaplan J, Palis J, Paw BH, Mootha VK. Discovery of genes essential for heme biosynthesis through large-scale gene expression analysis. Cell Metab. 2009;10(2):119-30.
78. Walden WE, Selezneva AI, Dupuy J, Volbeda A, Fontecilla-Camps JC, Theil EC, Volz K. Structure of dual function iron regulatory protein 1 complexed with ferritin IRE-RNA. Science. 2006;314(5807):1903-8.
79. Dupuy J, Volbeda A, Carpentier P, Darnault C, Moulis JM, Fontecilla-Camps JC. Crystal structure of human iron regulatory protein 1 as cytosolic aconitase. Structure. 2006;14(1):129-39. (Pubitemid 43350080)
80. Patrick L. Lead toxicity, a review of the literature. Part 1: Exposure, evaluation, and treatment. Altern Med Rev. 2006;11(1):2-22.
81. Warren MJ, Cooper JB, Wood SP, Shoolingin-Jordan PM. Lead poisoning, haem synthesis and 5-aminolaevulinic acid dehydratase. Trends Biochem Sci. 1998;23(6):217-21.
82. Kauppinen R, und zu FM. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families. Clin Chem. 2002;48(11):1891-900.
83. Jarup L. Hazards of heavy metal contamination. Br Med Bull. 2003;68:167-82.
84. Lidsky TI, Schneider JS. Lead neurotoxicity in children: basic mechanisms and clinical correlates. Brain. 2003;126(Pt 1):5-19.
85. Rabinowitz MB, Wetherill GW, Kopple JD. Kinetic analysis of lead metabolism in healthy humans. J Clin Invest. 1976;58(2):260-70.
86. Fleming DE, Boulay D, Richard NS, Robin JP, Gordon CL, Webber CE, Chettle DR. Accumulated body burden and endogenous release of lead in employees of a lead smelter. Environ Health Perspect. 1997;105(2):224-33.
87. Silbergeld EK, Schwartz J, Mahaffey K. Lead and osteoporosis: mobilization of lead from bone in postmenopausal women. Environ Res. 1988;47(1):79-94.
88. Silbergeld EK. Lead in bone: implications for toxicology during pregnancy and lactation. Environ Health Perspect. 1991;91:63-70.
89. Patrick L. Lead toxicity part II: the role of free radical damage and the use of antioxidants in the pathology and treatment of lead toxicity. Altern Med Rev. 2006;11(2):114-27.
90. Steenland K, Boffetta P. Lead and cancer in humans: where are we now? Am J Ind Med. 2000;38(3):295-9.
91. Ziegler EE, Edwards BB, Jensen RL, Mahaffey KR, Fomon SJ. Absorption and retention of lead by infants. Pediatr Res. 1978;12(1):29-34.
92. Grinblat B, Pour N, Malik Z. Regulation of porphyrin synthesis and photodynamic therapy in heavy metal intoxication. J Environ Pathol Toxicol Oncol. 2006;25(1-2):145-58.
93. Sakai T, Yanagihara S, Ushio K. Erythrocyte factors concerned in the inhibition of ALA-D by lead. Br J Ind Med. 1981;38(3):268-74.
94. Sakai T. Biomarkers of lead exposure. Ind Health. 2000;38(2):127-42.
95. Needleman H. Lead poisoning. Annu Rev Med. 2004;55:209-22.
96. McIntire MS, Angle CR. Air lead: relation to lead in blood of black school children defi cient in glucose-6-phosphate dehydrogenase. Science. 1972;177(48):520-2.
97. Bernstein LR. Mechanisms of therapeutic activity for gallium. Pharmacol Rev. 1998;50(4):665-82.
98. Seligman PA, Moran PL, Schleicher RB, Crawford ED. Treatment with gallium nitrate: evidence for interference with iron metabolism in vivo. Am J Hematol. 1992;41(4):232-40.
99. Hedley DW, Tripp EH, Slowiaczek P, Mann GJ. Effect of gallium on DNA synthesis by human T-cell lymphoblasts. Cancer Res. 1988;48(11):3014-8.
100. Jakupec MA, Keppler BK. Gallium in cancer treatment. Curr Top Med Chem. 2004;4(15):1575-83.
101. Jakupec MA, Galanski M, Arion VB, Hartinger CG, Keppler BK. Antitumour metal compounds: more than theme and variations. Dalton Trans. 2008;(2):183-94.
102. Chitambar CR, Matthaeus WG, Antholine WE, Graff K, OBrien WJ. Inhibition of leukemic HL60 cell growth by transferrin-gallium: effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea. Blood. 1988;72(6):1930-6.
103. Chitambar CR, Wereley JP, Matsuyama S. Galliuminduced cell death in lymphoma: role of transferring receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibition. Mol Cancer Ther. 2006;5(11):2834-43.
104. Straus DJ. Gallium nitrate in the treatment of lymphoma. Semin Oncol. 2003;30(2 Suppl 5):25-33.
105. Seth R, Yang S, Choi S, Sabean M, Roberts EA. In vitro assessment of copper-induced toxicity in the human hepatoma line, Hep G2. Toxicol In Vitro. 2004;18(4):501-9.
106. Sheline CT, Choi DW. Cu2+ toxicity inhibition of mitochondrial dehydrogenases in vitro and in vivo. Ann Neurol. 2004;55(5):645-53.
107. Maryon EB, Molloy SA, Zimnicka AM, Kaplan JH. Copper entry into human cells: progress and unanswered questions. Biometals. 2007;20(3-4):355-64.
108. Huffman DL, OHalloran TV. Function, structure, and mechanism of intracellular copper traffi cking proteins. Annu Rev Biochem. 2001;70:677-701.
109. Kelly EJ, Palmiter RD. A murine model of Menkes disease reveals a physiological function of metallothionein. Nat Genet. 1996;13(2):219-22.
110. Brewer GJ. The risks of copper toxicity contributing to cognitive decline in the aging population and to Alzheimers disease. J Am Coll Nutr. 2009;28(3): 238-42.
111. Morris MC, Evans DA, Tangney CC, Bienias JL, Schneider JA, Wilson RS, Scherr PA. Dietary copper and high saturated and trans fat intakes associated with cognitive decline. Arch Neurol. 2006;63(8):1085-8.
112. Karr JW, Kaupp LJ, Szalai VA. Amyloid-beta binds Cu2+ in a mononuclear metal ion binding site. J Am Chem Soc. 2004;126(41):13534-8.
113. Nakano E, Williamson MP, Williams NH, Powers HJ. Copper-mediated LDL oxidation by homocysteine and related compounds depends largely on copper ligation. Biochim Biophys Acta. 2004;1688(1): 33-42.
114. Nakayama K, Takasawa A, Ohyama T, Tamura M. Abnormal accumulation of porphyrin derivatives in the kidneys of Long-Evans Cinnamon rats, as evidenced by microspectrophotometry. Biochem Biophys Res Commun. 1998;242(1):164-9.
115. Nakayama K, Takasawa A, Terai I, Okui T, Ohyama T, Tamura M. Spontaneous porphyria of the Long-evans cinnamon rat: an animal model of Wilsons disease. Arch Biochem Biophys. 2000;375(2): 240-50.
116. Hait-Darshan R, Babushkin T, Malik Z. Regulation of heme synthesis and proteasomal activity by copper: possible implications for Wilsons disease. J Environ Pathol Toxicol Oncol. 2009;28(3):209-21.
117. Flanagan PR, McLellan JS, Haist J, Cherian G, Chamberlain MJ, Valberg LS. Increased dietary cadmium absorption in mice and human subjects with iron deficiency. Gastroenterology. 1978;74(5 Pt 1):841-6.
118. Valberg LS, Sorbie J, Hamilton DL. Gastrointestinal metabolism of cadmium in experimental iron deficiency. Am J Physiol. 1976;231(2):462-7.
119. Alfven T, Elinder CG, Carlsson MD, Grubb A, Hellstrom L, Persson B, Pettersson C, Spång G, Schütz A, Järup L. Low-level cadmium exposure and osteoporosis. J Bone Miner Res. 2000;15(8):1579-86.
120. Nordberg G, Jin T, Bernard A, Fierens S, Buchet JP, Ye T, Kong Q, Wang H. Low bone density and renal dysfunction following environmental cadmium exposure in China. Ambio. 2002;31(6):478-81.
121. Staessen JA, Roels HA, Emelianov D, Kuznetsova T, Thijs L, Vangronsveld J, Fagard R. Environmental exposure to cadmium, forearm bone density, and risk of fractures: prospective population study. Public Health and Environmental Exposure to Cadmium (PheeCad) Study Group. Lancet. 1999;353(9159):1140-4.
122. Seidal K, Jorgensen N, Elinder CG, Sjogren B, Vahter M. Fatal cadmium-induced pneumonitis. Scand J Work Environ Health. 1993;19(6):429-31. 123
123. Schwerdtle T, Ebert F, Thuy C, Richter C, Mullenders LH, Hartwig A. Genotoxicity of soluble and particulate cadmium compounds: impact on oxidative DNA damage and nucleotide excision repair. Chem Res Toxicol. 2010;23(2):432-42.
124. Perez G, Garbossa G, Di Risio C, Vittori D, Nesse A. Disturbance of cellular iron uptake and utilisation by aluminum. J Inorg Biochem. 2001;87(1-2):21-7.
125. Castorina A, Tiralongo A, Giunta S, Carnazza ML, Scapagnini G, DAgata V. Early effects of alumi-num chloride on beta-secretase mRNA expression in a neuronal model of ss-amyloid toxicity. Cell Biol Toxicol. 2010 (In press).
126. Stevanovic ID, Jovanovic MD, Colic M, Jelenkovic A, Bokonjic D, Ninkovic M. Nitric oxide synthase inhibitors protect cholinergic neurons against AlCl3 excitotoxicity in the rat brain. Brain Res Bull. 2010;81(6):641-6.
127. Shaw CA, Petrik MS. Aluminum hydroxide injections lead to motor defi cits and motor neuron degeneration. J Inorg Biochem. 2009;103(11):1555-62.